NCT00000774 arm group a87ff679a2f3e71d9181a67b7542122c [clinicaltrials_resource:NCT00000774/arm-group/a87ff679a2f3e71d9181a67b7542122c]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00000774 arm group a87ff679a2f3e71d9181a67b7542122c [clinicaltrials_resource:NCT00000774/arm-group/a87ff679a2f3e71d9181a67b7542122c]
Bio2RDF identifier
NCT00000774/arm-group/a87ff679a2f3e71d9181a67b7542122c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 7ff679a2f3e71d9181a67b7542122c
description [clinicaltrials_vocabulary:description]
Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
identifier
clinicaltrials_resource:NCT00000774/arm-group/a87ff679a2f3e71d9181a67b7542122c
title
NCT00000774 arm group a87ff679a2f3e71d9181a67b7542122c
@en
type
label
NCT00000774 arm group a87ff679 ...... ff679a2f3e71d9181a67b7542122c]
@en